SCHEMBL8232487

SCHEMBL8232487

C/C=C1\CN(S(=O)(=O)c2ccc(Cl)cc2)c2ccccc2C1=O

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 3/20 0.64
▸ KCNN4 O15554 2/20 0.64
▸ PSEN1 P49768 6/20 0.54
▸ PSEN2 P49810 6/20 0.54
▸ APH1B Q8WW43 6/20 0.54
▸ NCSTN Q92542 6/20 0.54
▸ APH1A Q96BI3 6/20 0.54
▸ PSENEN Q9NZ42 6/20 0.54
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MMP2 P08253 2/20 0.49
▸ CMA1 P23946 2/20 0.44
▸ CTSG P08311 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14280941 0.86 KCNA3 (0.60) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL3041480 0.79 KCNA3 (1.00) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL14280956 0.76 KCNA3 (0.59) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL28973111 0.75 KCNN4 (0.62) KCNA3KCNN4MEN1KMT2AMMP2
SCHEMBL29754844 0.75 KCNN4 (0.62) KCNA3KCNN4MEN1KMT2AMMP2
SCHEMBL8230676 0.74 KCNA3 (0.48) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2705507 0.73 KMT2A (0.68) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL28973103 0.72 MMP2 (0.47) KCNA3KCNN4MEN1KMT2AMMP2
SCHEMBL29754785 0.72 MMP2 (0.47) KCNA3KCNN4MEN1KMT2AMMP2
SCHEMBL2702553 0.72 KCNA3 (0.64) KCNA3KCNN4PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO disclosed
Send feedback